EUVIMEDEUVIMED entdecken
Crossref

Real-World Evidence of the Effect of Adjunctive Semaglutide on Weight Change, Glycemic Control, and Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes

Jonathan Mertens iD, Hennah T De Winter, Eveline Dirinck, Sven Francque, Christophe De Block

Diabetes Technology & Therapeutics · 2026

DOI: 10.1177/15209156251362497 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Technology & Therapeutics, 2026. Verfasst von Jonathan Mertens und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetology & Metabolism, Antwerp University Hospital, Antwerp, Belgium. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Glucagon-Like Peptides, Hypoglycemic Agents, Obesity. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Obesity is increasingly prevalent in type 1 diabetes (T1D), contributing to insulin resistance and metabolic dysfunction-associated steatotic liver disease (MASLD). While semaglutide has demonstrated weight loss, improved glycemic control, and cardiovascular benefits in type 2 diabetes, its use in T1D remains unapproved. Aims and Methods: This real-world study evaluates the effects of once-weekly semaglutide in overweight/obese adults with T1D after 12 months of follow-up. Inclusion criteria were stable glycemic control (ΔHbA1c < 0.3%), stable body weight (Δweight < 3%), and consistent total daily insulin requirement (TDI, ΔTDI < 5%) over the preceding year. Changes in weight, total daily insulin dose (TDI), glycated hemoglobin A1c (HbA1c), and metabolic markers, including controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), were assessed at baseline and 12 months.

Results

Among 42 subjects (53% male, age 46 ± 12 years, diabetes duration 28 ± 12 years, HbA1c 7.4 ± 0.8%, body mass index 32.2 ± 4.3 kg/m 2 ), 76.2% had obesity. Eight subjects discontinued treatment, mainly due to gastrointestinal intolerance. Mean relative weight loss was 13.3 ± 11.3% ( P < 0.001), with 76.4% attaining ≥5% weight loss and 61.7% attaining ≥10%. Obesity prevalence decreased to 29.4% ( P < 0.001). HbA1c decreased by 0.4 ± 0.6% ( P < 0.001), with 42% achieving a reduction of ≥0.5%. No significant changes in continuous glucose monitoring-derived parameters were observed in those with available data ( n = 28). TDI reduced by 13.6 ± 16.0% ( P < 0.001), whereas TDI/kg of body weight remained stable. In 23 subjects with serial hepatic imaging, MASLD prevalence reduced from 82.6% to 30.4% ( P < 0.001), CAP decreased by 45 ± 33 decibels/m, and significant fibrosis (based on LSM >8 kPa) declined from 20.6% to 4.5% ( P < 0.001).

Conclusion

Semaglutide in T1D was safe and well-tolerated and led to significant weight loss, improved glycemic control, and amelioration of MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Glucagon-Like PeptidesHypoglycemic AgentsObesityFatty LiverHumansMaleFemaleMiddle AgedAdultGlycemic ControlGlycated HemoglobinBlood GlucoseWeight Loss

Stichwörter der Autor:innen

BMIMASLDliver steatosissemaglutidetype 1 diabetesweight

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsGlycated HemoglobinBlood Glucose

Autor:innen und Institutionen

  • Department of Endocrinology, Diabetology & Metabolism, Antwerp University Hospital, Antwerp, Belgium.
  • Laboratory of Experimental Medicine and Paediatrics and member of the Infla-Med Centre of Excellence, Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp, Belgium.
  • Department of Gastroenterology & Hepatology, Antwerp University Hospital, Antwerp, Belgium.
  • Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp, Belgium.

ORCID-Profile: Jonathan Mertens

Zitieren

APA

Mertens, J., De Winter, H. T., Dirinck, E., Francque, S., & De Block, C. (2026). Real-World Evidence of the Effect of Adjunctive Semaglutide on Weight Change, Glycemic Control, and Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes. Diabetes Technology & Therapeutics. https://doi.org/10.1177/15209156251362497

Vancouver

Mertens J, De Winter HT, Dirinck E, Francque S, De Block C. Real-World Evidence of the Effect of Adjunctive Semaglutide on Weight Change, Glycemic Control, and Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes. Diabetes Technology & Therapeutics. 2026. doi:10.1177/15209156251362497

BibTeX
@article{Mertens2026,
  author = {Mertens, Jonathan and De Winter, Hennah T and Dirinck, Eveline and Francque, Sven and De Block, Christophe},
  title = {Real-World Evidence of the Effect of Adjunctive Semaglutide on Weight Change, Glycemic Control, and Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes},
  journal = {Diabetes Technology & Therapeutics},
  year = {2026},
  doi = {10.1177/15209156251362497}
}
Kostenlos starten →